Royalty Report: Drugs, Disease, Pharmaceuticals – Collection: 26279

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 18

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 18

Primary Industries

  • Drugs
  • Disease
  • Pharmaceuticals
  • Pain
  • Therapeutic
  • Gastrointestinal
  • Drug Discovery
  • Migraine

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26279

License Grant
The Licensor entered into a collaboration Agreement with the Licensee for the exclusive worldwide development and commercialization of Entereg for certain indications. The Licensor is responsible for the development of acute indications, such as postoperative ileus, and the Licensee is responsible for the development of chronic indications, such as opioid bowel dysfunction. In the United States, the Licensee and the Licensor are co-developing Entereg and intend to share profits or losses that result from the sale of the product.
License Property
Entereg is a drug which behaves as a peripherally acting µ-opioid antagonist. With limited ability to cross the blood–brain barrier, many of the undesirable side-effects of the opioid agonists such as constipation are minimized without affecting analgesia or precipitating withdrawal.

Opioid analgesics provide pain relief by stimulating opioid receptors located in the central nervous system. There are, however, opioid receptors throughout the body, including the GI tract. By binding to the receptors in the GI tract, opioid analgesics can slow gut motility and disrupt normal GI function that allows for the passage, absorption and excretion of ingested solid materials. This disruption can cause patients to experience significant discomfort and abdominal pain and may result in their reducing or eliminating their pain medication.
Entereg is a small molecule, mu-opioid receptor antagonist intended to block the adverse side effects of opioid analgesics on the GI tract without affecting analgesia. We are developing Entereg for both acute and chronic conditions.

Licensor is currently developing a compound known as alvimopan for postoperative bowel dysfunction and other gastrointestinal disorders.  Alvimopan is indicated for the management of postoperative ileus or management of post operative bowel dysfunction in open laparotomies except simple hysterectomies.

Product means a prescription pharmaceutical product that contains Compound as the sole active ingredient for use in the Field. For the avoidance of doubt, Product shall not include products sold in the OTC market.

Licensor Products means a POI Product, an OBD Acute Product or any Additional Product designated by the Parties as an Licensor Product.

Additional Product means a PONV Product and any Product other than a POI Product, an OBD Acute Product, an OBD Chronic Product, a Constipation Product or an IBS Product included by the Parties.

Licensor Housemark means the name and logo of Licensor.

Collaboration Products means the Licensor Products and the GI Products.

Compound means the peripheral mu antagonist having molecular formula(+)-[[2(S)-[[4(R)-(3-hydroxyphenyl)-3(R),4-dimethyl-1-piperidinyl]- methyl]-1-oxo-3-phenylpropyl]amino]acetic acid dihydrate, known generically as 'alvimopan', and all pharmaceutically acceptable salts and solvates thereof.

Constipation Product means a Product for the management of non-opioid induced forms of constipation or bowel dysfunction which such Product is not an IBS Product.

GI Product means an OBD Chronic Product, a Constipation Product, an IBS Product, or any Additional Product designated by the Parties as a GI Product.

POI Product means a Product for the prevention, treatment or management of post-operative ileus or post-operative bowel dysfunction.

PONV Product means a Product for the management of post-operative nausea or vomiting.

Field of Use
The Field means all uses of Compound in human beings except in products or formulations containing Compound and opioids.

The target audience is General Surgeons, Urologists, OB/Gyn Surgeons, Gastroenterologists, Colorectal Surgeons, Anesthesiologists, and, Abdominal Surgeons.

IPSCIO Record ID: 203524

License Grant
Licensor grants an exclusive, except as to Licensor for internal research purposes only and not for clinical development, license under Know How, the Licensed Patents arid the Process Licensed Patents, to develop, obtain Regulatory Approval for, use, make, have made, import, sell, and offer for sale New Compounds and New Products in the Territory.
License Property
The patents, related foreign equivalents and know-how relate to peripherally selective opioid antagonists.

The New Compound shall mean a chemical entity (including salts and solvates thereof, which shall be considered the same New Compound for purposes of this Agreement) covered by any valid and unexpired claim of Licensed Patents, but shall exclude in all cases the Roberts Agreement Compound.

The New Product means a finished, formulated pharmaceutical product containing a New Compound, together with all improvements and line extensions thereon which may be included in any supplement, modification or addition to the relevant Regulatory Approval to the extent that any such improvements or line extensions contain a New Compound.

Field of Use
The Field of Use means all uses as a Peripherally Selective Opioid Receptor Antagonist, where the term Peripherally Selective Opioid Receptor Antagonist shall mean a chemical entity that has a selectivity ratio of greater than 20 upon parenteral administration as measured by the ED-50 for antagonism of analgesia in the mouse writhing test in morphine-naive mice divided by the ED-50 for precipitation of diarrhea in the morphine-dependent mice test.

Licensee is developing  alvimopan, a peripherally selective mu opioid antagonist for management of postoperative ileus, opioid induced bowel dysfunction and certain other indications.  Alvimopan is in a class of medications called peripherally acting mu-opioid receptor antagonists. It works by protecting the bowel from the constipation effects of opioid (narcotic) medications that are used to treat pain after surgery.

IPSCIO Record ID: 111868

License Grant
Licensor grants an exclusive, world-wide license to make, have made, use, sell or import Product pursuant to the Intellectual Property Rights or any other Licensor Technical Information. The term of the license shall be either the term of Phase A or, if Licensee elects to proceed with Phase B, the sum of the terms of Phase A and Phase B.

Phase A is for completing studies sufficient to establish the therapeutic index of the Compound and of whether Licensee intends to initiate Phase B.  Phase B is for developing and commercializing the Compound or Product.

License Property
Licensor has acquired from a third party, an exclusive, world-wide license to make, have made, use or sell (+)-[2(S)-[4(R)-(3-hydroxyphenyl)-3(R),4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]-acetic acid and all pharmaceutically acceptable salts and solvates thereof (the Compound), with the right to sublicense.

ADL 8-2698 is a peripherally-acting, gastrointestinal tract-restricted mu opioid receptor antagonist.  ADL 8-2698 is for treatment of narcotic bowel dysfunction.
Narcotic bowel syndrome (NBS) is a subset of opioid bowel dysfunction that is characterized by chronic or frequently recurring abdominal pain that worsens with continued or escalating dosages of narcotics.  As a result of the undesired action of opioids on the gastrointestinal (GI) tract, patients receiving opioid medication for chronic pain often experience opioid-induced bowel dysfunction (OBD), the most common and debilitating symptom of which is constipation.

Field of Use
Licensee is engaged in the development and marketing of therapeutic products utilizing opiate receptor-mediated pathways.

Licensee are developing orally-administered ADL 8-2698 to block the adverse gastrointestinal side effects of narcotics without blocking the beneficial analgesic effects. These gastrointestinal side effects include narcotic bowel dysfunction, ileus, which is delayed recovery of bowel function after surgery, and nausea.

IPSCIO Record ID: 274836

License Grant
The United Kingdom Licensor hereby grants to Licensee, and Licensee hereby accepts, a fully paid-up, royalty-free, irrevocable, perpetual, non-terminable, transferable, exclusive (including as to Licensor and its Affiliates) and worldwide license, with the right to grant sublicenses, under Licensor Patents and Licenor Know-How, to research, develop, use, offer to sell, sell, import, export and otherwise exploit and commercialize the Product in the Territory.

Licensor hereby grants to Licensor a non-exclusive, non-sublicenseable license to use the Licensor Housemark, for a period not to exceed six (6) months after the Effective Date, in the Territory solely in conjunction with disposition of any inventory of the Product (and associated package inserts or outserts and monographs or packaging materials) that bear or contain the Licensor Housemark. After such six (6) month period, all Licensor Housemarks shall be removed from all inventory of the Product and any Product including any Licensor Housemarks shall, at Licensee option, be either (i) repackaged such that all inventory of the Product no longer bears or contains the Licensor Housemark or (ii) destroyed.

Licensor and Licensee hereby agree to terminate the Collaboration Agreement in its entirety effective as of the Effective Date for a royalty payment.

License Property
Product means the prescription pharmaceutical product currently sold in the Territory that contains the Compound whether or not as the sole active pharmaceutical ingredient and in any form or formulation.

Compound means the peripheral mu antagonist having molecular formula (+)-[[2(S)-[[4(R)-(3-hydroxyphenyl)-3(R),4-dimethyl-1-piperidinyl]-methyl]-1-oxo-3-phenylpropyl]amino]acetic acid dihydrate, known generically as “alvimopan”, and all pharmaceutically acceptable salts and solvates thereof.

Licensor Patent means all Patent Rights covering the Product in the Territory, which are owned by Licensor or Licensor’s Affiliates as of the Effective Date, or as to which Licensor or Licensor’s Affiliates otherwise are licensed as of the Effective Date, which Patent Rights cover the use, offer for sale, sale or importation of the Product in the Territory.

Licensor Housemark means the name and logo of Licensor or an Affiliate of Licensor as identified by Licensor to Licensee from time to time.

Alvimopan (trade name Entereg) is a drug which behaves as a peripherally acting µ-opioid antagonist. With the limited ability to cross the blood–brain barrier and reach the µ-opioid receptors of the central nervous system, the clinically undesirable effects of centrally acting opioid antagonists (like reversal of opioid-mediated analgesia) are avoided without affecting the intended blockade of µ-opioid receptors in the gastrointestinal tract.

Field of Use
The Licensee’s commercial product, ENTEREG® (alvimopan), is indicated to accelerate upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis.

IPSCIO Record ID: 279342

License Grant
Licensor hereby grants to the Puerto Rico Licensee in the Field an exclusive (even as to Licensor, other than as set forth in this agreement (Retained Rights)) license under the Licensor Technology and Joint Technology, with the right to sublicense as set forth in this agreement (Sublicenses), to make, have made, use, Develop, sell, offer to sell, have sold, import, export, and otherwise exploit and Commercialize the Compound and Products in the Territory. Licensee acknowledges that with respect to those Licensor Patent Rights that are Controlled by Licensor pursuant to the Third Party Agreements, the foregoing license is subject to the rights of the Third Party licensors under such Third Party Agreements.
License Property
Compound means R-methyinaltrexoun (R-MNTX) which is chemically defined as morphinanium, 17R, 17-(cyclopropylmethyl)-4, 5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, bromide, (5a)-(9C1), and its pharmacologically acceptable salts, together with their solvates, hydrates, hemihydrates, metabolites, pro-drugs, esters, and if applicable, any isomers or racemates thereof, but excluding any of the foregoing olecules whose primary mechanism of action is as an opioid agonist. The “Compound” does not include the Excluded Molecules.

Licensor Patent Rights are identified as
4,719,215 – Quaternary derivatives of noroxymorphone which relieve nausea and emesis
4,861,781 – Quaternary derivatives of noroxymorphone which relieve nausea and emesis
5,102,887 – Method for reducing emesis and nausea induced by the administration of an emesis causing agent

To relieve pain, narcotic medications such as morphine activate specific opioid receptors located in the central nervous system – the brain and spinal cord. Opioids, however, also interact with these receptors outside of the central nervous system, resulting in side effects, which can be debilitating, including constipation, urinary retention and severe itching. MNTX is designed to block peripheral opioid receptors whose activation causes these side effects. As MNTX does not cross the blood-brain barrier, it does not interfere with brain-centered pain relief.

Field of Use
The agreement is for the joint development and commercialization of methylnaltrexone (MNTX) for the treatment of opioid-induced side effects, including constipation and post-operative bowel dysfunction. These medical conditions are major therapeutic challenges in the management of gastrointestinal function in individuals treated with opioids for pain or in patients following serious or prolonged surgeries.

IPSCIO Record ID: 279343

License Grant
Licensee is hereby exercising its option to acquire an exclusive license to make, use, and sell N-methylnaltrexone and any of its congeners under U.S. Patent 4,176,186.  In all other respects the agreement of May 8, 1985 shall remain in effect as previously agreed.
License Property
Patents shall mean U.S. Patent 4,176,186 as well as any patent application filed respecting other uses of the Compound, and corresponding foreign patents.

4,176,186 – Quaternary derivatives of noroxymorphone which relieve intestinal immobility

Compound shall mean N-methylnaltrexone having the chemical structure C21H26BrNO.

Field of Use
MNTX is a selective, peripheral, opioid-receptor antagonist that reverses certain side effects induced by opioid use. MNTX competes with opioid analgesics for binding sites on opioid receptors, but is unable to cross the blood-brain barrier. As a result, MNTX “turns off” the effects of opioid analgesics outside the central nervous system, including the gastrointestinal tract, but does not interfere with opioid activity within the central nervous system. Therefore, MNTX does not block the pain relief that the opioids provide. To date, patients treated with MNTX in addition to opioid pain medications have experienced a reversal of many of the side effects induced by the opioids and have reported no decline in pain relief. MNTX has been studied in numerous clinical trials. To date, MNTX has been generally well tolerated and highly active in blocking opioid-related side effects without interfering with pain relief.

IPSCIO Record ID: 314635

License Grant
South Korean Licensor shall, and hereby does, grant to Licensee an exclusive (even as to Licensor and its Affiliates), royalty-bearing right and license, including the right to sublicense in accordance with this Agreement, under the Licensor Intellectual Property and Licensor’s interest in the Joint Intellectual Property, to Develop, Manufacture, use and Commercialize, including filing for, obtaining and maintaining Regulatory Approval for, Products in the Field in the Territory.
License Property
Product means any pharmaceutical preparation containing one or more Compounds either as its only active ingredient(s) or as part of a Combination Product. For the avoidance of doubt, nothing in this Agreement grants to Licensee or Licensor any right or license under any Patent Rights or Know-How Controlled by Licensor or Licensee, respectively, with respect to any Other API.

Compound means YH12852, which has the chemical structure set forth in this agreement, together with all analogs, derivatives, metabolites, stereoisomers, polymorphs, formulations, mixtures or compositions thereof, and any existing or future improved or modified versions of the foregoing developed by or on behalf of Licensee, its Affiliates or Sublicensees.

Compound (S)-N-(1-(2-((4-amino-3-nitrophenyl)amino)-6-propylpyrimidin-4-yl)pyrrolidin-3-yl)acetamide

Licensor Patent Rights means all Patent Rights in the Territory that are Controlled by Licensor or any of its Affiliates as of the Effective Date or thereafter during the Term (other than Joint Patent Rights) that Cover any Compound or Product. The Licensor Patent Rights existing as of the Effective Date are set forth on Schedule 1.57; provided, however, that, if Licensor is acquired by a Third Party, “Licensor Patent Rights” shall exclude any Patent Rights that (a) are Controlled by such Third Party or the Affiliates of such Third Party (other than Licensor and Licensor Pre-Existing Affiliates) and (b) were not Controlled by Licensor or any of the Licensor Pre-Existing Affiliates immediately prior to the closing of such acquisition transaction; provided further that, if, after the closing of such acquisition, any such Licensor Excluded Affiliate has or acquires Control of any Patent Right that Covers the Development, Manufacture or Commercialization of any Compound or Product and that is used to Develop, Manufacture or Commercialize any such Compound or Product, such additional Patent Right that is Controlled by such Licensor Excluded Affiliate shall be included in Licensor Patent Rights.

9,890,138 – Diaminopyrimidine derivatives and processes for the preparation thereof
10,227,330 – Diaminopyrimidine derivatives and processes for the preparation thereof
9,850,227 – Diaminopyrimidine derivatives and processes for the preparation thereof

Licensee is a global pharmaceutical company offering one-stop custom synthesis services of active pharmaceutical products (APIs) and intermediates.

YH12852 is a novel, potent and highly selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. Other 5-HT receptor agonists with less 5-HT4 selectivity have been shown to successfully treat GI mobility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia and gastroparesis.

Field of Use
YH12852 is a small molecule drug in development for the treatment of functional gastrointestinal (GI) disorders (FGID).

IPSCIO Record ID: 266021

License Grant
The parties entered into an exclusive license agreement  for the commercialization of Symproic® (naldemedine tosylate) (the Product) in the United States including Puerto Rico (the Territory) for opioid-induced constipation in adult patients with chronic non-cancer pain (the Field).
License Property
Symproic® (naldemedine) is a prescription medicine used to treat constipation that is caused by prescription pain medicines called opioids, in adults with long-lasting (chronic) pain that is not caused by active cancer.
Field of Use
Opioid-induced constipation (OIC) often occurs in patients administered opioids for chronic noncancer pain. Patients commonly experience hard, infrequent, and incomplete bowel movements with bloating and straining, which may impact pain management and quality of life.  Opioid-induced constipation is attributed to activation of enteric µ-opioid receptors, which decrease bowel tone and contractility and increase colonic fluid absorption and anal sphincter tone while reducing rectal sensation. This leads to harder stools, which can be difficult to pass.

IPSCIO Record ID: 3196

License Grant
Licensor hereby grant to Licensee, and Licensee hereby accepts in respect of the Licensed Technology and the Licensors’ interest in the Joint Technology  (a) the exclusive license, even as to the Licensor and their Affiliates, with the right to grant Sublicenses (i) to Develop the Compound and Products in the Territory for use and Commercialization in the Field in the Territory and (ii) to Commercialize Products in the Field in the Territory; and (b) a non-exclusive license, with the right to grant Sublicenses to Manufacture or have Manufactured in the Territory (i) Products for use or Commercialization by Licensee and its Sublicensees under the license granted and (ii) Compound for incorporation into such Products.

The Licensor granted License of relevant know-how, patent rights and technology,for Relistor® (methylnaltrexone bromide) subcutaneous injection, to the Licensee, a leading gastrointestinal disease specialty company.

License Property
Relistor (methylnaltrexone bromide) subcutaneous injection is a first-in-class therapy for opioid-induced constipation (OIC).

OIC is the constipation that often arises when patients take opioids for pain relief.

Field of Use
Opioid-induced constipation (OIC) often occurs in patients administered opioids for chronic noncancer pain. Patients commonly experience hard, infrequent, and incomplete bowel movements with bloating and straining, which may impact pain management and quality of life.  Opioid-induced constipation is attributed to activation of enteric µ-opioid receptors, which decrease bowel tone and contractility and increase colonic fluid absorption and anal sphincter tone while reducing rectal sensation. This leads to harder stools, which can be difficult to pass.

IPSCIO Record ID: 7784

License Grant
The Licensor entered into a global License Agreement with the Licensee granting the Licensee a worldwide, exclusive, perpetual, royalty-bearing License under patents and other intellectual property to develop, market and sell MovantikTM and MovantikTM fixed-dose combination products.
License Property
MovantikTM was developed using oral small molecule polymer conjugate technology.  MovantikTM is an orally-available peripherally-acting mu-opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC), which is a common side effect of prescription opioid.

Opioid-induced constipation (OIC) often occurs in patients administered opioids for chronic noncancer pain. Patients commonly experience hard, infrequent, and incomplete bowel movements with bloating and straining, which may impact pain management and quality of life.  Opioid-induced constipation is attributed to activation of enteric µ-opioid receptors, which decrease bowel tone and contractility and increase colonic fluid absorption and anal sphincter tone while reducing rectal sensation. This leads to harder stools, which can be difficult to pass.

Field of Use
The Licensee has agreed to use commercially reasonable efforts to develop one MovanikTM fixed-dose combination product and has the right to develop multiple products which combine MovantikTM with opioids.

IPSCIO Record ID: 323765

License Grant
Licensor granted Licensee exclusive, worldwide (excluding Europe, Canada and Israel) commercialization and development rights to Movantik® (naloxegol).

The parties amended the License Agreement to grant Licensee also the exclusive commercialization and development rights to Movantik® (naloxegol) in Israel.

License Property
Movantik® (naloxegol) is a gastrointestinal drug. Movantik® works by helping to keep opioids from attaching to something called “mu-receptors” in your bowel.
Field of Use
The field of use is for the treatment of opioid-induced constipation in adults with non-cancer pain.

Opioid-induced constipation (OIC) often occurs in patients administered opioids for chronic noncancer pain. Patients commonly experience hard, infrequent, and incomplete bowel movements with bloating and straining, which may impact pain management and quality of life.  Opioid-induced constipation is attributed to activation of enteric µ-opioid receptors, which decrease bowel tone and contractility and increase colonic fluid absorption and anal sphincter tone while reducing rectal sensation. This leads to harder stools, which can be difficult to pass.

IPSCIO Record ID: 2810

License Grant
Licensor grants an exclusive license to make, have made, use or sell for use in the Field within the United States and its territories (Puerto Rico, Guam), Canada and Mexico.  The Compound and Product pursuant to all Licensor’s Intellectual Property Rights.
License Property
Licensor has discovered a compound internally designated as LY315535 (5,434,174) which may be useful in the treatment of functional gastrointestinal disorders and other indications.

Compound means 2-di-n-propylamino-8-(isoxazol-5-yl)-1,2,3,4-tetrahydronaphthalene and all pharmaceutically acceptable salts and solvates.

Field of Use
Field means products for Gastrointestinal Indications.  
Gastrointestinal Indications means disease states, such as excess gastric acid secretion, inflammatory bowel disease, irritable bowel syndrome, gastroesophagael reflux disease, esophagitis, dyspepsia, proctitis, hemorrhoids, gastrointestinal ulceration, nausea and vomiting and constipation and diarrhea, which are characterized by abnormalities of the Digestive System, regardless of the mechanism involved in such disease states.

IPSCIO Record ID: 26353

License Grant
The Licensor and the Licensee entered in to a worldwide exclusive Agreement for the development and commercialization of Relistor.
License Property
Relistor is for the treatment of opioid induced constipation, specifically designed to block the constipating effects of opioid pain medications in the gastrointestinal tract.
Field of Use
The Licensee will further developing and commercializing Rlistor, including completing clinical development necessary to support regulatory marketing approvals for potential new indications and formulations of the drug, such as oral methylnaltrexone.

IPSCIO Record ID: 2796

License Grant
The Licensor's lead product is Relistorâ„¢ (methylnaltrexone bromide).
License Property
On April 24, 2008, Relistor subcutaneous injection was approved by the U.S. Food and Drug Administration for sale in the United States for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Our collaboration partner, the Licensee, commenced sales of Relistor subcutaneous injection in the U.S. in June 2008.
Field of Use
Opioid-induced constipation (OIC) often occurs in patients administered opioids for chronic noncancer pain. Patients commonly experience hard, infrequent, and incomplete bowel movements with bloating and straining, which may impact pain management and quality of life.  Opioid-induced constipation is attributed to activation of enteric µ-opioid receptors, which decrease bowel tone and contractility and increase colonic fluid absorption and anal sphincter tone while reducing rectal sensation. This leads to harder stools, which can be difficult to pass.

IPSCIO Record ID: 279382

License Grant
Licensor grants an exclusive license under Licensor Know-How and Licensed Patents to make, have made, use, sell, offer for sale, and import Compound and Product in the Field in theTerritory.
License Property
Licensor has certain intellectual property rights relating to its non-selective AMPA/Kainate receptor antagonist.

The patents include, but are not limited to Excitatory amino acid receptor antagonists, and, Process for preparing isoquinoline compounds, and, Synthesis of cis-decahydroisoquinoline-3-carboxylic acids.

AMPA/kainate, or AK, antagonist assets including its lead drug candidate, tezampanel, and NGX426.

Tezampanel has a range of effects which may be useful for medicinal purposes, as well as its applications in scientific research. It suppresses both the withdrawal symptoms from morphine and other opioids, and the development of tolerance,as well as having and analgesic effects in its own right. It also has anxiolytic effects in animal studies and has been suggested as a candidate for the treatment of anxiety in humans.

Field of Use
The Field means all human therapeutic indications including, but not limited to, migraine, post-operative pain and epilepsy.

IPSCIO Record ID: 2809

License Grant
Licensor grants an exclusive, worldwide license to make, have made, use or sell the Compound and Product pursuant to all Licensor Intellectual Property Rights.
License Property
Licensor has discovered a compound internally designated as LY353433 which may be useful in the treatment of functional gastrointestinal disorders and other indications.

Compound means 1-(1-methylethyl)-N-[2-[4-[(tricyclo[3.3.1.1 (3,7)]-dec-1-ylcarbonyl)amino]-1-piperidinyl]ethyl]-1H-indazole-3-carboxamide and all pharmaceutically acceptable salts and solvates thereof.

IPSCIO Record ID: 7344

License Grant
The Licensee entered into an exclusive License Agreement (with a right to subLicense) with the Licensor, a nonprofit medical research facility, for the rights to novel modulators of sphingosine phosphate receptors, including modulators to the S1P1R.
License Property
The technology Licensed covers RPC1063.

RMS  RPC1063 is a novel, oral, once daily, selective and potent S1P1R modulator. RMS is a chronic autoimmune disorder of the central nervous system (CNS), characterized by recurrent acute exacerbations (relapses) of neurological dysfunction followed by variable degrees of recovery with clinical stability between relapses (remission).

RPC1063 for the treatment of UC IBD is comprised of two chronic, autoimmune, GI inflammatory disorders UC and Crohn's Disease (CD). UC is a GI inflammatory disorder involving ulcers in the colon and is characterized by a chronic course of remissions and exacerbations. Patients suffer from a multitude of GI symptoms, including diarrhea, rectal bleeding and abdominal pain.

Field of Use
RPC1063, is being developed as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD).

IPSCIO Record ID: 203448

License Grant
Licensor grants to the Licensee, of the Netherlands, an exclusive license, with the right to sublicense to its Affiliates, under the Licensors Technology to develop, have developed, import, make, have made, use; offer to sell, sell, commercialize and distribute the Licensed Product in the Field in the Territory for the purpose of Manufacturing, seeking Regulatory Approval for and/or Commercializing Licensed Products.
License Property
Marketing partnership is for Dyloject® (diclofenac sodium for injection).  Dyloject is an injectable formulation of diclofenac in Phase 3 clinical development in the United States and marketed in the United Kingdom. Diclofenac is a prescription nonsteroidal anti-inflammatory drug ('NSAID') that is widely prescribed to treat post-operative pain.  Dyloject provides an attractive alternative to other NSAIDs for the treatment of post-operative and acute pain to decrease the need for morphine or other opioids.

Compound means diclofenac sodium having the chemical name 2- [ (2,6-dichlorophenyl)amino] benzeneacetic acid, monosodium salt.

The Licensed Product means any intramuscular or intravenous injectable form of a pharmaceutical product that contains the Licensed Formulation either alone or in combination with one or more other active ingredients. For the avoidance of doubt and unless otherwise mutually agreed by the Parties, each in its sole discretion, Licensed Product excludes oral, inhalable and other formulations and dosage forms that are not intramuscular or intravenous injectable formulations or dosage forms.

The patents include Pharmaceutical Composition, Stable Injectable Compositions, Formulations Of Low Dose Non- Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin, Formulations Of Low Dose Diclofenac And Beta-Cyclodextrin, and, Methods Of Treating Pain While Minimizing Adverse Effects On Platelet Function.

Field of Use
The Field means the treatment, prevention, modulation or diagnosis of any disease, disorder or condition in humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.